Van Belle E, Tio F O, Couffinhal T, Maillard L, Passeri J, Isner J M
Department of Medicine (Cardiology), St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Mass, USA.
Circulation. 1997 Jan 21;95(2):438-48. doi: 10.1161/01.cir.95.2.438.
Because prior studies have established the critical role of the endothelium in preventing vascular thrombosis and intimal thickening, we designed a series of experiments to determine the feasibility of percutaneous local catheter delivery of recombinant protein to accelerate development of an intact endothelial monolayer after stent implantation.
Balloon injury followed by percutaneous delivery of a 15-mm-long, balloon-expandable metallic stent was performed in 64 rabbit external iliac arteries (baseline diameter, 2.67 +/- 0.07 mm). Planimetric time-course analysis disclosed < 20% stent endothelialization at 4 days, < 40% at 7 days, and near-complete endothelialization at 28 days. The reporter protein horseradish peroxidase and the endothelial cell-specific recombinant protein vascular endothelial growth factor (VEGF) were each effectively delivered from a local delivery catheter (channel balloon catheter, ChB) after stent implantation. Although local catheter delivery (of vehicle control) itself mildly retarded the extent of stent endothelialization (10.6 +/- 2.9%) versus no local delivery (25.5 +/- 6.6%, P = .045), local ChB delivery of 100 micrograms VEGF overcame this catheter effect: By day 7, stent endothelialization was nearly complete (91.8 +/- 3.8%) (P < .0001 versus no local delivery). Consequently, stent thrombus was reduced in the VEGF-treated group (mural thrombus, 5.3 +/- 3.7%) versus no local delivery (29.3 +/- 6.8%, P = .006). Occlusive thrombus was seen only in the absence of local VEGF administration.
(1) Local delivery of recombinant protein to the arterial wall is feasible after stent implantation, and (2) local delivery of the endothelial cell mitogen VEGF accelerates stent endothelialization, reducing stent thrombosis. These results thus establish a novel means by which the safety and/or bioactivity of endovascular stents may be further enhanced.
由于先前的研究已证实内皮细胞在预防血管血栓形成和内膜增厚方面的关键作用,我们设计了一系列实验,以确定经皮局部导管递送重组蛋白以加速支架植入后完整内皮单层形成的可行性。
对64只兔的髂外动脉(基线直径2.67±0.07mm)进行球囊损伤,随后经皮递送一个15mm长的球囊扩张金属支架。平面时程分析显示,4天时支架内皮化程度小于20%,7天时小于40%,28天时接近完全内皮化。支架植入后,报告蛋白辣根过氧化物酶和内皮细胞特异性重组蛋白血管内皮生长因子(VEGF)均能从局部递送导管(通道球囊导管,ChB)有效递送。尽管局部导管递送(载体对照)本身相对于无局部递送而言轻度延迟了支架内皮化程度(10.6±2.9%对25.5±6.6%,P = 0.045),但局部ChB递送100μg VEGF克服了这种导管效应:到第7天,支架内皮化几乎完成(91.8±3.8%)(与无局部递送相比,P < 0.0001)。因此,VEGF治疗组的支架血栓减少(壁血栓,5.3±3.7%),而无局部递送组为(29.3±6.8%,P = 0.006)。仅在未进行局部VEGF给药时观察到闭塞性血栓。
(1)支架植入后向动脉壁局部递送重组蛋白是可行的,(2)局部递送内皮细胞有丝分裂原VEGF可加速支架内皮化,减少支架血栓形成。这些结果因此确立了一种可进一步提高血管内支架安全性和/或生物活性的新方法。